298 related articles for article (PubMed ID: 7693418)
1. Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of epirubicin.
Robert J
Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
[TBL] [Abstract][Full Text] [Related]
3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
4. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
[TBL] [Abstract][Full Text] [Related]
5. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer.
Jakobsen P; Steiness E; Bastholt L; Dalmark M; Lorenzen A; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS
Cancer Chemother Pharmacol; 1991; 28(1):63-8. PubMed ID: 2040035
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
Robert J; Monnier A; Poutignat N; Hérait P
Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
Camaggi CM; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F
Cancer Chemother Pharmacol; 1988; 21(3):221-8. PubMed ID: 3162849
[TBL] [Abstract][Full Text] [Related]
14. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
[TBL] [Abstract][Full Text] [Related]
15. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
Ganzina F
Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
[TBL] [Abstract][Full Text] [Related]
16. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker GL; Faulds D
Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG; Gradishar WJ
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
Coukell AJ; Faulds D
Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
